Sinn, Natalie, Milte, Catherine M., Street, Steven J., Buckley, Jonathan D., Coates, Alison M., Petkov, John, Howe, Peter R.C.

Depressive symptoms may increase the risk of progressing from mild cognitive impairment (MCI) to dementia. Consumption of n-3 PUFA may alleviate both cognitive decline and depression. The aim of the present study was to investigate the benefits of supplementing a diet with n-3 PUFA, DHA and EPA, for depressive symptoms, quality of life (QOL) and […]

Howard, Robert, McShane, Rupert, Lindesay, James, Ritchie, Craig, Baldwin, Ashley, Barber, Robert, Burns, Alistair, Dening, Tom, Findlay, David, Holmes, Clive, Hughes, Alan, Jacoby, Robin, Jones, Rob, Jones, Roy, McKeith, Ian, Macharouthu, Ajay, O'Brien, John, Passmore, Peter, Sheehan, Bart, Juszczak, Edmund, Katona, Cornelius, Hills, Robert, Knapp, Martin, Ballard, Clive, Brown, Richard, Banerjee, Sube, Onions, Caroline, Griffin, Mary, Adams, Jessica, Gray, Richard, Johnson, Tony, Bentham, Peter, Phillips, Patrick

Background: Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer’s disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease.; Methods: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer’s […]

Vigen, Cheryl L. P., Mack, Wendy J., Keefe, Richard S. E., Sano, Mary, Sultzer, David L., Stroup, T. Scott, Dagerman, Karen S., Hsiao, John K., Lebowitz, Barry D., Lyketsos, Constantine G., Tariot, Pierre N., Zheng, Ling, Schneider, Lon S.

Objective: The impact of the atypical antipsychotics olanzapine, quetiapine, and risperidone on cognition in patients with Alzheimer’s disease is unclear. The authors assessed the effects of time and treatment on neuropsychological functioning during the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease study (CATIE-AD).; Method: CATIE-AD included 421 outpatients with Alzheimer’s disease and psychosis or agitated/aggressive […]

Kwok, T., Lee, J., Law, C. B., Pan, P. C., Yung, C. Y., Choi, K. C., Lam, L. C.

Introduction: Whether homocysteine lowering by B vitamins can reduce cognitive decline in Alzheimer disease and vascular dementia patients is unclear.; Methods and Materials: 140 subjects with mild to moderate Alzheimer disease or vascular dementia were randomly assigned to take 1 mg of methylcobalamin and 5 mg of folic acid, or placebo once daily for 24 […]

Rosenberg, Paul B., Drye, Lea T., Martin, Barbara K., Frangakis, Constantine, Mintzer, Jacobo E., Weintraub, Daniel, Porsteinsson, Anton P., Schneider, Lon S., Rabins, Peter V., Munro, Cynthia A., Meinert, Curtis L., Lyketsos, Constantine G.

Objective: Depression is common in Alzheimer disease (AD), and antidepressants are commonly used for its treatment, however, evidence for antidepressant efficacy in this population is lacking. The authors conducted a multicenter, randomized, placebo-controlled trial titled “Depression in Alzheimer’s Disease-2” to assess the efficacy and tolerability of sertraline for depression in AD.; Methods: One hundred thirty-one […]

Isik, Ahmet Turan, Bozoglu, Ergun, Naharci, M. Ilkin, Kilic, Selim

Background: Galantamine, a cholinesterase inhibitor, is used as a first-line drug in the treatment of Alzheimer’s disease (AD). However, it may have vagotonic effects, which may cause bradycardia and/or heart block in patients with or without a history of cardiac disease.; Objective: The purpose of this study was to evaluate the effects of galantamine on […]